Together, these results showed that miR-92a was elevated in CD4+ T cells from patients with MS and that miR-92a silencing in T cells of patients with MS effectively shifted the Th cell balance toward Tregs and away from Th17 cells. This evidence concerns the gene CD4 and myeloid sarcoma.